Information Provided By:
Fly News Breaks for August 11, 2017
CANF
Aug 11, 2017 | 07:58 EDT
Maxim analyst Jason McCarthy started Can-Fite Biopharma with a Buy rating, stating that the company has multiple shots on goal in "blockbuster-sized indications" with its A3AR targeting drug piclidenoson. The analyst, who models piclidenoson commercialization in rheumatoid arthritis in 2022 followed by psoriasis in 2023, set a $7 price target on Can-Fite shares.
News For CANF From the Last 2 Days
There are no results for your query CANF